Gerresheimer's Financial Crossroads: Loan Default Threatens Restructuring Plans

Gerresheimer faces technical default due to a delayed audit, prompting urgent asset sales and restructuring while negotiating with banks and facing a widened BaFin probe.

The packaging specialist Gerresheimer finds itself navigating a precarious financial landscape, with a critical loan covenant breach complicating urgent restructuring efforts. As the company races to sell assets and shore up liquidity, a delayed audit report has triggered a technical default, casting uncertainty over its entire operational roadmap.

Audit Delay Triggers Covenant Breach

A central and immediate challenge is the absence of an audited financial statement for fiscal year 2025. This missing document has placed the company in technical default on its credit agreements. Management is now engaged in intensive negotiations with its banking partners to secure waivers and extensions, aiming to prevent the cancellation of its credit facilities. Consequently, the quarterly report scheduled for mid-month and the annual general meeting have been postponed indefinitely.

Compounding the accounting delay are expanded regulatory and internal probes. Following internal violations of IFRS requirements by certain employees, a second auditing firm is now examining revenue recognition and balance sheet practices. Simultaneously, German financial watchdog BaFin has widened its own investigation. The regulator's scrutiny now includes leasing liabilities of approximately €65.5 million and capitalized development costs totaling €29.4 million.

Liquidity Drive Through Asset Sales and Cuts

To bolster its cash position in the short term, Gerresheimer has mandated Morgan Stanley to oversee the sale of its U.S. subsidiary, Centor. The transaction, focused on pharmaceutical packaging, is targeted for completion within the current year. At the end of 2024, this division was carried on the books at a value of €292 million.

Operational restructuring is proceeding in parallel. The company is shuttering its Chicago Heights plant by year-end, shifting capacity to facilities in Italy and India. These cuts come at a significant cost: for the concluded 2025 fiscal year, the group anticipates non-cash impairment charges between €220 million and €240 million, primarily linked to technology projects and the U.S. manufacturing site.

Conditional Outlook Amid Investor Positioning

Despite the turbulence, management has issued a conditional forecast for the current year. It projects revenues of €2.3 to €2.4 billion, with an adjusted EBITDA margin of 18% to 19%. However, achieving these targets is strictly contingent upon successful credit negotiations and the outcome of the BaFin investigations.

On the markets, investors are adjusting their stakes amid the depressed share price. Institutional players like the CastleKnight Master Fund and Deka Investment have been establishing new positions. Conversely, one hedge fund recently increased its short interest to 0.62%.

The coming month of June represents a crucial deadline. The anticipated delivery of the audited 2025 financial statements at the earliest by then will provide creditors with clarity on the firm's true financial foundation. Until that point, the execution of operational goals and the planned Centor divestment remain entirely dependent on the success of ongoing lender discussions.